Form 4: Travere Therapeutics CCO Sells Shares Under 10b5-1 Plan

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, sold 4,980 shares of common stock at $40 per share under a pre-arranged 10b5-1 plan.

Summary

• Peter Heerma, the Chief Commercial Officer of Travere Therapeutics, Inc. (TVTX), reported a sale of common stock.
• The transaction involved the disposition of 4,980 shares of common stock.
• The shares were sold at a price of $40 per share.
• The total value of the shares sold was $199,200 (4,980 shares * $40/share).
• Following this transaction, Peter Heerma beneficially owns 113,013 shares of common stock directly.
• The sale was executed on December 24, 2025.
• This transaction was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a pre-scheduled insider sale under a 10b5-1 plan, which typically indicates personal financial planning rather than a reaction to new company-specific information. It is a routine disclosure for an insider transaction.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• An insider, the Chief Commercial Officer, sold a portion of their common stock holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure and does not inherently provide insight into broader industry trends or competitive landscape. It reflects an individual's personal financial planning rather than a corporate strategic move.

Stakeholder Impact

• Shareholders: The sale by a Chief Commercial Officer could be viewed with slight caution, though the 10b5-1 plan mitigates concerns about it being based on new negative information. It represents a minor reduction in insider ownership.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled insider stock sale under a 10b5-1 plan. Such transactions are typically for personal financial management and are not usually indicative of the company's operational performance or future prospects. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate as investors should rely on broader company fundamentals and market conditions.

Keywords

Travere Therapeutics, TVTX, Peter Heerma, Chief Commercial Officer, Insider Sale, Form 4, 10b5-1 Plan, Common Stock